Jonathan Luke Heeney
Also known as: Jon Heeney
University of Cambridge, National Institutes of Health / University of Guelph, University of Guelph
0000-0003-2702-1621
About
I am the Professor of Comparative Pathology at the University of Cambridge and Head of the Lab of Viral Zoonotics (LVZ) and a Fellow and former vice Master of Darwin College. I study viruses that are transmitted from animals to humans (Zoonotic Viruses) that have the potential to cause high consequence human disease outbreaks. My expertise is in Viral disease, Immunology and Vaccine development. A detailed understanding of the deleterious versus protective immune responses to RNA viruses enables us to design safer vaccines with broader protection for prevention and control from highly variable RNA viruses. Research at the LVZ spans human and veterinary medicine as we trace the origins and evolution of pathogens and their hosts. In 2017 we established new technology to make vastly improved vaccine antigens, and spun-out DIOSynVax Ltd out of Cambridge to deliver NextGen vaccine antigens for vaccines to prevent future pandemics.
Employment
-
University of Cambridge Professor of Comparative Pathology2007 - Present
Education
-
University of Cambridge ScD2007 - 2012
-
University of Cambridge MA2007 - 2007
-
National Institutes of Health / University of Guelph PhD1986 - 1989
-
University of Guelph DVSc(Path)1984 - 1986
-
University of Guelph DVM1980 - 1984
-
University of Guelph BSc Biology1977 - 1980
Projects & Funding
Projects & funding information is unavailable.
Publications (348)
- Impact of Pre-Existing Adenovirus Immunity on Vaccine Immunity Induced by ChAdOx1 nCoV-19 in Immunodeficient Patients Save
- Digitally Immune-Optimised Next-Generation Influenza Vaccine Provides Cross-Clade Protection Against Emerging H5Nx Viruses Save
- Covering All Bases: A Computational Method to Design Broad-spectrum T-cell-inducing Vaccines Applied to Betacoronaviruses Save
- Accelarated immune ageing is associated with COVID-19 disease severity. Save
- Immunological insights into COVID-19 in Southern Nigeria. Save
- Replicative fitness and pathogenicity of primate lentiviruses in lymphoid tissue, primary human and chimpanzee cells: relation to possible jumps to humans. Save
- Effect of second booster vaccinations and prior infection against SARS-CoV-2 in the UK SIREN healthcare worker cohort. Save
- Post-acute COVID-19 neuropsychiatric symptoms are not associated with ongoing nervous system injury. Save
- Immune imprinting and next-generation coronavirus vaccines Save
- Evolution of protective SARS-CoV-2-specific B- and T-cell responses upon vaccination and Omicron breakthrough infection Save